Identity
What is BPC-157?
- Type
- Synthetic pentadecapeptide
- CAS Number
- 137525-51-0
- Sequence
- GEPPPGKPADDAGLV
- Amino acids
- 15
- Molecular weight
- 1419.5 g/mol
- Research family
- Tissue repair
- Use classification
- Research Use Only
Science Library · Cytoprotection & repair
BPC-157 the science.
BPC-157 is a synthetic pentadecapeptide (15 amino acids) related to a protective sequence identified in gastric juice. It is among the most widely studied peptides in preclinical tissue-repair research, where investigators examine cellular survival, blood-vessel formation, and recovery in animal models. Everything below comes from laboratory and animal studies.
View the BPC-157 product page →
15 aa
Pentadecapeptide
Angiogenesis
Pathway focus
Preclinical
Evidence stage
Rodent & cell
Model systems
How it works
Mechanism at a glance
Compound
BPC-157
Signaling
VEGFR2–eNOS pathway
Effect
Angiogenesis & cell migration
Studied for
Tissue-repair models
Evidence to date
In vitro
Animal
Human
Evidence to date: largely animal and cell models; limited human data.
What it is
BPC-157 (“body-protective compound 157”) is a stable synthetic peptide with the sequence GEPPPGKPADDAGLV. It is notably robust in laboratory conditions, which is part of why it is used so often as a research tool for studying cytoprotection — the ways cells defend themselves against stress and injury.
Pathways under study
Preclinical work has examined several mechanisms:
- Angiogenesis — formation of new blood vessels, studied via VEGFR2–Akt–eNOS signaling in cell and animal models.
- Nitric-oxide pathway — interactions with NO signaling and vascular tone.
- Cell migration & growth factors — effects on the movement and survival of fibroblasts and tendon-derived cells.
What research has explored
BPC-157 literature is largely preclinical, concentrated in rodent and cell-culture models:
- Tendon & soft-tissue models. A 2011 study reported that BPC-157 promoted tendon-cell outgrowth, survival, and migration in vitro.
- Vascular signaling. A 2020 study examined effects on vasomotor tone and Src–caveolin-1–eNOS signaling.
- Broad cytoprotection. Animal studies have looked at gut, muscle, and other tissue-response models; a 2025 systematic review summarized growing interest in orthopaedic/sports-medicine research contexts.
These are findings in animals and cells. Human clinical evidence for BPC-157 remains limited.
Current state of the evidence
The BPC-157 evidence base is predominantly preclinical; rigorous human clinical-trial data is limited. No human safety, dosing, or efficacy is established here. BPC-157 is supplied strictly as a research material for laboratory investigation.
Compound Snapshot
At a glance
Evidence base
Research maturity
Preclinical
Animal & in vitro
Limited human data
Maturity
Largely preclinical
Extensive rodent and cell-culture literature; limited rigorous human data.
Translation
Not established in humans
Animal and in-vitro findings do not establish human safety, dosing, or benefit.
Sources & References
Peer-reviewed research and database records
PubChem
BPC-157 compound record
CID 9941957 · formula, molecular weight, sequence. View SourceJ. Applied Physiology / PubMed
BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
2011 · PMID 21030672 · DOI 10.1152/japplphysiol.00945.2010 View SourceScientific Reports / Nature
Modulatory effects of BPC 157 on vasomotor tone and Src–Caveolin-1–eNOS signaling
2020 · Scientific Reports 10, 17078 View SourcePubMed
BPC-157 literature search
NCBI PubMed index for primary papers, reviews, and PMID-linked records. View SourceFor research use only. Not for human or veterinary use. These products have not been evaluated by the FDA. Nothing on this page is medical advice or a therapeutic claim.
Catalog